Roche sets up a breast cancer déjà vu
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
What now for NK-cell engagers?
Big pharma interest remains, but the mood is fast turning gloomy.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Kura harks back to its roots
After menin, the company tries again with farnesyl transferase.
